Detection of drugs of abuse in urine using the Bruker Toxtyper™: Experiences in a routine clinical laboratory setting
Clinical Mass Spectrometry · 2017
DOI: 10.1016/j.clinms.2017.08.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Mass Spectrometry, 2017. Verfasst von M Ott und 4 weiteren Autor:innen. Beteiligte Einrichtung: Zentralinstitut für Klinische Chemie und Laboratoriumsmedizin, Klinikum Stuttgart, Stuttgart, Germany. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Urine screening can be used to detect misuse of illicit drugs and validate opioid replacement therapy compliance. It is common that immunochemical assays are combined with GC-MS for these applications. Bruker has recently released an ion trap mass spectrometer, called Toxtyper™, with the potential to replace current screening algorithms to detect drug misuse. Here, we compare our current strategy of urine screening for misuse of cannabis, amphetamines, cocaine, opiates, benzodiazepine, methadone, sufentanil, and pregabalin to the Toxtyper protocols provided by the manufacturer. The analytical performance of the instrument was determined on a selected drug panel and with 188 urine samples being compared to establish concordance between our currently established approach and the Toxtyper. The lower limits of detection and identification for acetylcodeine, amphetamine, benzoylecgonine, methadone, and nordiazepam were below the common cut-offs for immunological screening assays and comparable to GC-MS. Imprecision and accuracy, both within- and between-series, were consistently 90% for all drugs, except for pregabalin. Cannabis misuse could not be detected due to the limited sensitivity of the Toxtyper assay protocols used and the inherent imprecision of the assay. Our study has revealed that a considerable portion of our current time-consuming protocol for screening drugs of abuse in urine, based on the combination of multiple analytical methods, could be consolidated by the Toxtyper for a majority of the most-relevant substances in our patient population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Zentralinstitut für Klinische Chemie und Laboratoriumsmedizin, Klinikum Stuttgart, Stuttgart, Germany.
Zitieren
APA
Ott, M., Berbalk, K., Plecko, T., Wieland, E., & Shipkova, M. (2017). Detection of drugs of abuse in urine using the Bruker Toxtyper™: Experiences in a routine clinical laboratory setting. Clinical Mass Spectrometry. https://doi.org/10.1016/j.clinms.2017.08.002
Vancouver
Ott M, Berbalk K, Plecko T, Wieland E, Shipkova M. Detection of drugs of abuse in urine using the Bruker Toxtyper™: Experiences in a routine clinical laboratory setting. Clinical Mass Spectrometry. 2017. doi:10.1016/j.clinms.2017.08.002
BibTeX
@article{Ott2017,
author = {Ott, M and Berbalk, K and Plecko, T and Wieland, E and Shipkova, M},
title = {Detection of drugs of abuse in urine using the Bruker Toxtyper™: Experiences in a routine clinical laboratory setting},
journal = {Clinical Mass Spectrometry},
year = {2017},
doi = {10.1016/j.clinms.2017.08.002}
}
EUVIMED